Stock comparison
Corcept Therapeutics
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.41B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$43.63B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 75B | IDXX |
| Benjamin Graham | 86C | 80A | CORT |
| Philip Fisher | 64C | 75B | IDXX |
| Peter Lynch | 32F | 71B | IDXX |
| Joel Greenblatt | 47D | 83C | IDXX |
| Charlie Munger | 60C | 87A | IDXX |
| Terry Smith | 68C | 84A | IDXX |
Side-by-side metrics
| Metric | CORT | IDXX |
|---|---|---|
| Market cap | $6.41B | $43.63B |
| P/E (TTM) | 122.0x | 39.0x |
| EV/EBIT | 131.9x | 31.6x |
| ROIC (TTM) | -1.23% | 40.66% |
| Gross margin | 98.25% | 62.05% |
| Net margin | 6.23% | 24.63% |
| Revenue CAGR 5y | 20.1% | 7.56% |
| EPS CAGR 5y | -0.52% | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Debt / Equity0.0xvs 0.7x+98%
- Revenue CAGR 5y20.1%vs 7.56%+62%
- Gross margin98.25%vs 62.05%+37%
IDXX leads on
- EPS CAGR 5y10.79%vs -0.52%+105%
- ROIC (TTM)40.66%vs -1.23%+103%
- Market cap$43.63Bvs $6.41B+85%
- EV/EBIT31.6xvs 131.9x+76%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.